Vaccines, Blood & Biologics
July 22, 2004 Approval Letter
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Food and Drug Administration
1401 Rockville Pike
Rockville, MD 20852-1448
July 22, 2004
Submission Tracking Number (STN): BL 103385/5004
Matthew E. Klamrzynski
100 Abbott Park Road
Abbott Park, IL 60064-3500
Dear Mr. Klamrzynski:
Your request to supplement your Biologics License Application for Human Immunodeficiency Virus Types 1 and 2/Enzyme Immuno Assay (EIA)/Recombinant)to allow a labeling change for the Abbott HIVAB HIV-1/HIV-2 (rDNA) EIA, to extend the indications for use to include cadaveric serum specimen testing., has been approved.
This information has been placed in your biologics license file. Please keep a copy of this letter available for review at the time of FDA inspections.
--- signature ---
Hira L. Nakhasi, Ph.D.
Division of Emerging and Transfusion Transmitted Diseases
Office of Blood Research and Review
Center for Biologics Evaluation and Research